The majority of patients with type 2 diabetes mellitus have uncontrolled glycemia, blood pressure and lipid levels and struggle to achieve targets set by current guidelines. In 2010, subgroup analyses of the ACCORD trial further underscored the need to tailor treatment to each individual.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Skyler, J. S. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32, 187–192 (2009).
Riddle, M. C. et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 33, 983–990 (2010).
ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575–1585 (2010).
ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563–1574 (2010).
The ACCORD Study Group and ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N. Engl. J. Med. 363, 233–244 (2010).
Ismail-Beigi, F. et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376, 419–430 (2010).
Kahn, R. et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet 375, 1365–1374 (2010).
Buse, J. B. et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes. A randomized, controlled trial. Ann. Intern. Med. 2010 Dec 6 [Epub ahead of print].
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares competing interests with the following companies:
Consultant:
Abbott
Akesis
Amylin
AstraZeneca
Bayhill Therapeutics
Becton-Dickinson
Biodel
Boehringer Ingelheim
Bristol-Myers Squibb
Daichi Sankyo
Dexcom
Eli Lilly
Exsulin
Genentech (Hoffman LaRoche)
GI Dynamics
GlaxoSmithKline
GlycoMark
Insulet
Intuity Medical
Johnson & Johnson
Liposcience
MannKind
MicroIslet
Novo Nordisk
Orexigen
Spherix
Pfizer
Veritas
Versartis
Wyeth
Grant/research support:
Amylin
Bristol-Myers Squibb
Dexcom
Eli Lilly
Fujisawa
Genentech (Hoffman LaRoche)
Halozyme
Interkrin
Johnson & Johnson
Medtronic
Merck
Novartis
Novo Nordisk
Osiris
Pfizer
Sanofi-Aventis
Tolerex
Transition Therapeutics
Stock holder:
Insulet
Rights and permissions
About this article
Cite this article
Buse, J. Individualizing treatment targets in diabetes care. Nat Rev Endocrinol 7, 67–68 (2011). https://doi.org/10.1038/nrendo.2010.230
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2010.230
